Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): Part II. Prognosis, management, and future directions

Journal of the American Academy of Dermatology

Volumn 70, Issue 2, 2014, Pages 223.e1-223.e17

  Jawed, Sarah I ^a   Myskowski, Patricia L ^a   Horwitz, Steven ^a   Moskowitz, Alison ^a   Querfeld, Christiane ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

cutaneous T cell lymphoma; immunomodulators; mycosis fungoides; phototherapy; prognosis; S zary syndrome; skin directed treatment; staging; systemic treatment; targeted therapies; topical corticosteroids; topical nitrogen mustard; topical retinoids rexinoids

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; BEXAROTENE; BORTEZOMIB; BRENTUXIMAB VEDOTIN; CHLORMETHINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DENILEUKIN DIFTITOX; DOXORUBICIN; GAMMA INTERFERON; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; IMMUNOMODULATING AGENT; INTERFERON; INTERLEUKIN DERIVATIVE; LENALIDOMIDE; METHOTREXATE; METHOXSALEN; PRALATREXATE; PREDNISONE; PROTEIN KINASE C INHIBITOR; PSORALEN; PYRIMIDINE; RETINOID; ROMIDEPSIN; TAZAROTENE; UNINDEXED DRUG; VINCRISTINE; VORINOSTAT; DERMATOLOGICAL AGENT; IMMUNOLOGIC FACTOR;

AGE; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BURN; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CHILL; COMORBIDITY; CUTANEOUS T CELL LYMPHOMA; CYTOMEGALOVIRUS INFECTION; DEPRESSION; DRUG DOSE REDUCTION; DRUG EFFICACY; DYSGEUSIA; DYSPNEA; ECG ABNORMALITY; FATIGUE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEPATITIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOPIGMENTATION; HYPOTENSION; HYPOTHYROIDISM; INFECTIOUS COMPLICATION; INFORMATION; INFUSION RELATED REACTION; INJECTION SITE REACTION; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; LYMPH NODE METASTASIS; MUCOSA INFLAMMATION; MYALGIA; MYCOSIS FUNGOIDES; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PANCREATITIS; PERIPHERAL NEUROPATHY; PHOTOTHERAPY; PRIORITY JOURNAL; PRURITUS; PUVA; QT PROLONGATION; RASH; RECOMMENDED DRUG DOSE; SEZARY SYNDROME; SKIN ABRASION; SKIN ALLERGY; SKIN ATROPHY; SKIN IRRITATION; STRIA; THROMBOCYTOPENIA; TOTAL SKIN ELECTRON THERAPY; ULCER; ULTRAVIOLET A RADIATION; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; VASCULAR LEAK SYNDROME; VOMITING; WEIGHT REDUCTION; ADJUVANT THERAPY; DRUG DELIVERY SYSTEM; FEMALE; INTRADERMAL DRUG ADMINISTRATION; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MEDICAL EDUCATION; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; SKIN NEOPLASMS; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADRENAL CORTEX HORMONES; COMBINED MODALITY THERAPY; DERMATOLOGIC AGENTS; DRUG DELIVERY SYSTEMS; EDUCATION, MEDICAL, CONTINUING; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MECHLORETHAMINE; MYCOSIS FUNGOIDES; PHOTOPHERESIS; PHOTOTHERAPY; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RETINOIDS; RISK ASSESSMENT; SEZARY SYNDROME; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84892666008     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2013.08.033     Document Type: Review

References (211)

1. E.A. Olsen, A.H. Rook, J. Zic, Y. Kim, P. Porcu, and C. Querfeld et al. Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC) J Am Acad Dermatol 64 2011 352 404
2. E.A. Olsen, S. Whittaker, Y.H. Kim, M. Duvic, H.M. Prince, and S.R. Lessin et al. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer J Clin Oncol 29 2011 2598 2607
3. S.M. Horwitz, E.A. Olsen, M. Duvic, P. Porcu, and Y.H. Kim Review of the treatment of mycosis fungoides and Sézary syndrome: a stage-based approach J Natl Compr Canc Netw 6 2008 436 442
4. S.I. Lamberg, and P.A. Bunn Jr. Cutaneous T-cell lymphomas. Summary of the Mycosis Fungoides Cooperative Group-National Cancer Institute Workshop Arch Dermatol 115 1979 1103 1105
5. E. Olsen, E. Vonderheid, N. Pimpinelli, R. Willemze, Y. Kim, and R. Knobler et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC) Blood 110 2007 1713 1722
6. R. Talpur, L. Singh, S. Daulat, P. Liu, S. Seyfer, and T. Trynosky et al. Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009 Clin Cancer Res 18 2012 5051 5060
7. Y.H. Kim, H.L. Liu, S. Mraz-Gernhard, A. Varghese, and R.T. Hoppe Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome: clinical prognostic factors and risk for disease progression Arch Dermatol 139 2003 857 866
8. Y.H. Kim, R.A. Jensen, G.L. Watanabe, A. Varghese, and R.T. Hoppe Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis Arch Dermatol 132 1996 1309 1313
9. N.S. Agar, E. Wedgeworth, S. Crichton, T.J. Mitchell, M. Cox, and S. Ferreira et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal J Clin Oncol 28 2010 4730 4739
10. E. Diamandidou, M. Colome, L. Fayad, M. Duvic, and R. Kurzrock Prognostic factor analysis in mycosis fungoides/Sézary syndrome J Am Acad Dermatol 40 1999 914 924
11. E. Diamandidou, M. Colome-Grimmer, L. Fayad, M. Duvic, and R. Kurzrock Transformation of mycosis fungoides/Sézary syndrome: clinical characteristics and prognosis Blood 92 1998 1150 1159
12. E.A. Fraser-Andrews, A.J. Woolford, R. Russell-Jones, P.T. Seed, and S.J. Whittaker Detection of a peripheral blood T cell clone is an independent prognostic marker in mycosis fungoides J Invest Dermatol 114 2000 117 121
13. C. Pitzalis, N. Pipitone, and M. Perretti Regulation of leukocyte-endothelial interactions by glucocorticoids Ann N Y Acad Sci 966 2002 108 118
14. R.A. Schwartzman, and J.A. Cidlowski Glucocorticoid-induced apoptosis of lymphoid cells Int Arch Allergy Immunol 105 1994 347 354
15. P.J. Barnes, and M. Karin Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases N Engl J Med 336 1997 1066 1071
16. C. Berthelot, A. Rivera, and M. Duvic Skin directed therapy for mycosis fungoides: a review J Drugs Dermatol 7 2008 655 666
17. E.M. Farber, H.S. Zackheim, R.P. McClintock, and A.J. Cox Jr. Treatment of mycosis fungoides with various strengths of fluocinolone acetonide cream Arch Dermatol 97 1968 165 172
18. E.M. Farber, A.J. Cox, J. Steinberg, and R.P. McClintock Therapy of mycosis fungoides with topically applied fluocinolone acetonide under occlusive dressing Cancer 19 1966 237 245
19. H.S. Zackheim Treatment of mycosis fungoides/Sézary syndrome: the University of California, San Francisco (UCSF) approach Int J Dermatol 42 2003 53 56
20. H.J. Cohen, and R.L. Baer Observations upon the use of topical triamcinolone acetonide preparations in various concentrations Dermatologica 122 1961 116 119
21. H.S. Zackheim, M. Kashani-Sabet, and S. Amin Topical corticosteroids for mycosis fungoides. Experience in 79 patients Arch Dermatol 134 1998 949 954
22. Y.H. Kim, G. Martinez, A. Varghese, and R.T. Hoppe Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience Arch Dermatol 139 2003 165 173
23. R.T. Hoppe, E.A. Abel, D.G. Deneau, and N.M. Price Mycosis fungoides: management with topical nitrogen mustard J Clin Oncol 5 1987 1796 1803
24. N.M. Price, D.G. Deneau, and R.T. Hoppe The treatment of mycosis fungoides with ointment-based mechlorethamine Arch Dermatol 118 1982 234 237
25. D.L. Ramsay, P.S. Halperin, and A. Zeleniuch-Jacquotte Topical mechlorethamine therapy for early stage mycosis fungoides J Am Acad Dermatol 19 1988 684 691
26. E.C. Vonderheid, E.T. Tan, A.F. Kantor, L. Shrager, B. Micaily, and E.J. Van Scott Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma J Am Acad Dermatol 20 1989 416 428
27. E.C. Vonderheid, E.J. Van Scott, P.E. Wallner, and W.C. Johnson A 10-year experience with topical mechlorethamine for mycosis fungoides: comparison with patients treated by total-skin electron-beam radiation therapy Cancer Treat Rep 63 1979 681 689
28. H. Zachariae, K. Thestrup-Pedersen, and H. Søgaard Topical nitrogen mustard in early mycosis fungoides. A 12-year experience Acta Derm Venereol 65 1985 53 58
29. S.R. Lessin, M. Duvic, J. Guitart, A.G. Pandya, B.E. Strober, and E.A. Olsen et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides JAMA Dermatol 149 2013 25 32
30. L.M. Lindahl, M. Fenger-Gron, and L. Iversen Topical nitrogen mustard therapy in patients with mycosis fungoides or parapsoriasis J Eur Acad Dermatol Venereol 27 2013 163 168
31. J. de Quatrebarbes, E. Esteve, M. Bagot, P. Bernard, M. Beylot-Barry, and M. Delaunay et al. Treatment of early-stage mycosis fungoides with twice-weekly applications of mechlorethamine and topical corticosteroids: a prospective study Arch Dermatol 141 2005 1117 1120
32. C. Querfeld, L.V. Nagelli, S.T. Rosen, T.M. Kuzel, and J. Guitart Bexarotene in the treatment of cutaneous T-cell lymphoma Expert Opin Pharmacother 7 2006 907 915
33. C. Zhang, P. Hazarika, X. Ni, D.A. Weidner, and M. Duvic Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action Clin Cancer Res 8 2002 1234 1240
34. D. Breneman, M. Duvic, T. Kuzel, R. Yocum, J. Truglia, and V.J. Stevens Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma Arch Dermatol 138 2002 325 332
35. N. Apisarnthanarax, R. Talpur, S. Ward, X. Ni, H.W. Kim, and M. Duvic Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study J Am Acad Dermatol 50 2004 600 607
36. N.H. Cox, M.L. Turbitt, J. Ashworth, and R.M. Mackie Distribution of T cell subsets and Langerhans cells in mycosis fungoides, and the effect of PUVA therapy Clin Exp Dermatol 11 1986 564 568
37. Y. Tokura, N. Seo, H. Yagi, and M. Takigawa Photoactivational cytokine-modulatory action of 8-methoxypsoralen plus ultraviolet A in lymphocytes, monocytes, and cutaneous T cell lymphoma cells Ann N Y Acad Sci 941 2001 185 193
38. E.K. Yoo, A.H. Rook, R. Elenitsas, F.P. Gasparro, and B.R. Vowels Apoptosis induction of ultraviolet light A and photochemotherapy in cutaneous T-cell lymphoma: relevance to mechanism of therapeutic action J Invest Dermatol 107 1996 235 242
39. O. Oguz, B. Engin, and E.H. Aydemir The influence of psoralen + ultraviolet A treatment on the duration of remission and prognosis in mycosis fungoides J Eur Acad Dermatol Venereol 17 2003 483 485
40. G. Roupe, M.H. Sandstrom, and C. Kjellstrom PUVA in early mycosis fungoides may give long-term remission and delay extracutaneous spread Acta Derm Venereol 76 1996 475 478
41. J.J. Herrmann, H.H. Roenigk Jr., A. Hurria, T.M. Kuzel, E. Samuelson, and A.W. Rademaker et al. Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up J Am Acad Dermatol 33 1995 234 242
42. H. Honigsmann, W. Brenner, W. Rauschmeier, K. Konrad, and K. Wolff Photochemotherapy for cutaneous T cell lymphoma. A follow-up study J Am Acad Dermatol 10 1984 238 245
43. L. Molin, K. Thomsen, G. Volden, and O. Groth Photochemotherapy (PUVA) in the pretumour stage of mycosis fungoides: a report from the Scandinavian Mycosis Fungoides Study Group Acta Derm Venereol 61 1981 47 51
44. D.V. Briffa, A.P. Warin, C.I. Harrington, and S.S. Bleehen Photochemotherapy in mycosis fungoides. A study of 73 patients Lancet 2 1980 49 53
45. N.J. Lowe, D.J. Cripps, P.A. Dufton, and C.F. Vickers Photochemotherapy for mycosis fungoides: a clinical and histological study Arch Dermatol 115 1979 50 53
46. C. Querfeld, S.T. Rosen, T.M. Kuzel, K.A. Kirby, H.H. Roenigk Jr., and B.M. Prinz et al. Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy Arch Dermatol 141 2005 305 311
47. V. Chiarion-Sileni, A. Bononi, C.V. Fornasa, M. Soraru, M. Alaibac, and E. Ferrazzi et al. Phase II trial of interferon-alpha-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma Cancer 95 2002 569 575
48. T.M. Kuzel, H.H. Roenigk Jr., E. Samuelson, J.J. Herrmann, A. Hurria, and A.W. Rademaker et al. Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome J Clin Oncol 13 1995 257 263
49. H.H. Roenigk Jr., T.M. Kuzel, A.P. Skoutelis, E. Springer, G. Yu, and W. Caro et al. Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma J Invest Dermatol 95 6 Suppl 1990 198S 205S
50. M.S. Duthie, I. Kimber, and M. Norval The effects of ultraviolet radiation on the human immune system Br J Dermatol 140 1999 995 1009
51. P.V. Diederen, H. van Weelden, C.J. Sanders, J. Toonstra, and W.A. van Vloten Narrowband UVB and psoralen-UVA in the treatment of early-stage mycosis fungoides: a retrospective study J Am Acad Dermatol 48 2003 215 219
52. M. Guckian, C.D. Jones, J.P. Vestey, E.J. Cooper, R. Dawe, and N.K. Gibbs et al. Immunomodulation at the initiation of phototherapy and photochemotherapy Photodermatol Photoimmunol Photomed 11 1995 163 169
53. G. Boztepe, S. Sahin, M. Ayhan, G. Erkin, and F. Kilemen Narrowband ultraviolet B phototherapy to clear and maintain clearance in patients with mycosis fungoides J Am Acad Dermatol 53 2005 242 246
54. V. Brazzelli, M. Antoninetti, S. Palazzini, F. Prestinari, and G. Borroni Narrow-band ultraviolet therapy in early-stage mycosis fungoides: study on 20 patients Photodermatol Photoimmunol Photomed 23 2007 229 233
55. O. Dereure, E. Picot, C. Comte, D. Bessis, and B. Guillot Treatment of early stages of mycosis fungoides with narrowband ultraviolet B. A clinical, histological and molecular evaluation of results Dermatology 218 2009 1 6
56. R.C. Gathers, L. Scherschun, F. Malick, D.P. Fivenson, and H.W. Lim Narrowband UVB phototherapy for early-stage mycosis fungoides J Am Acad Dermatol 47 2002 191 197
57. S.Z. Ghodsi, Z. Hallaji, K. Balighi, F. Safar, and C. Chams-Davatchi Narrow-band UVB in the treatment of early stage mycosis fungoides: report of 16 patients Clin Exp Dermatol 30 2005 376 378
58. G. Gokdemir, B. Barutcuoglu, D. Sakiz, and A. Koslu Narrowband UVB phototherapy for early-stage mycosis fungoides: evaluation of clinical and histopathological changes J Eur Acad Dermatol Venereol 20 2006 804 809
59. A. Hofer, L. Cerroni, H. Kerl, and P. Wolf Narrowband (311-nm) UV-B therapy for small plaque parapsoriasis and early-stage mycosis fungoides Arch Dermatol 135 1999 1377 1380
60. Y. Kural, N. Onsun, S. Aygin, C. Demirkesen, and N. Buyukbabani Efficacy of narrowband UVB phototherapy in early stage of mycosis fungoides J Eur Acad Dermatol Venereol 20 2006 104 105
61. F. Pavlotsky, A. Barzilai, R. Kasem, D. Shpiro, and H. Trau UVB in the management of early stage mycosis fungoides J Eur Acad Dermatol Venereol 20 2006 565 572
62. T. Xiao, L.X. Xia, Z.H. Yang, C.D. He, X.H. Gao, and H.D. Chen Narrow-band ultraviolet B phototherapy for early stage mycosis fungoides Eur J Dermatol 18 2008 660 662
63. S. Kanokrungsee, N. Rajatanavin, S. Rutnin, and V. Vachiramon Efficacy of narrowband ultraviolet B twice weekly for hypopigmented mycosis fungoides in Asians Clin Exp Dermatol 37 2012 149 152
64. R.J. Black, and A.T. Gavin Photocarcinogenic risk of narrowband ultraviolet B (TL-01) phototherapy: early follow-up data Br J Dermatol 154 2006 566 567
65. I. Man, I.K. Crombie, R.S. Dawe, S.H. Ibbotson, and J. Ferguson The photocarcinogenic risk of narrowband UVB (TL-01) phototherapy: early follow-up data Br J Dermatol 152 2005 755 757
66. M. Weischer, A. Blum, F. Eberhard, M. Rocken, and M. Berneburg No evidence for increased skin cancer risk in psoriasis patients treated with broadband or narrowband UVB phototherapy: a first retrospective study Acta Derm Venereol 84 2004 370 374
67. M.L. Lokitz, and H.K. Wong Bexarotene and narrowband ultraviolet B phototherapy combination treatment for mycosis fungoides Photodermatol Photoimmunol Photomed 23 2007 255 257
68. R.T. Hoppe Mycosis fungoides: radiation therapy Dermatol Ther 16 2003 347 354
69. B.D. Smith, and L.D. Wilson Cutaneous lymphomas Semin Radiat Oncol 17 2007 158 168
70. R.T. Hoppe Total skin electron beam therapy in the management of mycosis fungoides Front Radiat Ther Oncol 25 1991 80 89
71. C.E. Introcaso, B. Micaily, S.K. Richardson, J.M. Junkins-Hopkins, J.S. Yoon, and E.J. Kim et al. Total skin electron beam therapy may be associated with improvement of peripheral blood disease in Sézary syndrome J Am Acad Dermatol 58 2008 592 595
72. G.W. Jones, D. Rosenthal, and L.D. Wilson Total skin electron radiation for patients with erythrodermic cutaneous T-cell lymphoma (mycosis fungoides and the Sézary syndrome) Cancer 85 1999 1985 1995
73. D.M. Chinn, S. Chow, Y.H. Kim, and R.T. Hoppe Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides Int J Radiat Oncol Biol Phys 43 1999 951 958
74. G.W. Jones, R.T. Hoppe, and E. Glatstein Electron beam treatment for cutaneous T-cell lymphoma Hematol Oncol Clin North Am 9 1995 1057 1076
75. D. Navi, N. Riaz, Y.S. Levin, N.C. Sullivan, Y.H. Kim, and R.T. Hoppe The Stanford University experience with conventional-dose, total skin electron-beam therapy in the treatment of generalized patch or plaque (T2) and tumor (T3) mycosis fungoides Arch Dermatol 147 2011 561 567
76. P.A. Quiros, G.W. Jones, B.M. Kacinski, I.M. Braverman, P.W. Heald, and R.L. Edelson et al. Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides) Int J Radiat Oncol Biol Phys 38 1997 1027 1035
77. D. Roberge, T. Muanza, G. Blake, C. Shustik, T. Vuong, and C.R. Freeman Does adjuvant alpha-interferon improve outcome when combined with total skin irradiation for mycosis fungoides? Br J Dermatol 156 2007 57 61
78. L.D. Wilson, G.W. Jones, D. Kim, D. Rosenthal, I.R. Christensen, and R.L. Edelson et al. Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides J Am Acad Dermatol 43 2000 54 60
79. L.D. Wilson, A.L. Licata, I.M. Braverman, R.L. Edelson, P.W. Heald, and A.M. Feldman et al. Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy Int J Radiat Oncol Biol Phys 32 1995 987 995
80. G. Jones, J. McLean, D. Rosenthal, J. Roberts, and D.N. Sauder Combined treatment with oral etretinate and electron beam therapy in patients with cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome) J Am Acad Dermatol 26 1992 960 967
81. C. Harrison, J. Young, D. Navi, N. Riaz, B. Lingala, and Y. Kim et al. Revisiting low-dose total skin electron beam therapy in mycosis fungoides Int J Radiat Oncol Biol Phys 81 2011 e651 e657
82. N.M. Price Radiation dermatitis following electron beam therapy. An evaluation of patients ten years after total skin irradiation for mycosis fungoides Arch Dermatol 114 1978 63 66
83. L.D. Wilson, B.M. Kacinski, and G.W. Jones Local superficial radiotherapy in the management of minimal stage IA cutaneous T-cell lymphoma (mycosis fungoides) Int J Radiat Oncol Biol Phys 40 1998 109 115
84. G.W. Cotter, R.J. Baglan, T.H. Wasserman, and W. Mill Palliative radiation treatment of cutaneous mycosis fungoides - a dose response Int J Radiat Oncol Biol Phys 9 1983 1477 1480
85. K.J. Neelis, E.C. Schimmel, M.H. Vermeer, N.J. Senff, R. Willemze, and E.M. Noordijk Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas Int J Radiat Oncol Biol Phys 74 2009 154 158
86. T.O. Thomas, P. Agrawal, J. Guitart, S.T. Rosen, A.W. Rademaker, and C. Querfeld et al. Outcome of patients treated with a single-fraction dose of palliative radiation for cutaneous T-cell lymphoma Int J Radiat Oncol Biol Phys 85 2013 747 753
87. K. Camphausen, and P.J. Tofilon Inhibition of histone deacetylation: a strategy for tumor radiosensitization J Clin Oncol 25 2007 4051 4056
88. O.E. Akilov, C. Grant, R. Frye, S. Bates, R. Piekarz, and L.J. Geskin Low-dose electron beam radiation and romidepsin therapy for symptomatic cutaneous T-cell lymphoma lesions Br J Dermatol 167 2012 194 197
89. R.S. Siegel, B. Martone, J. Guitart, E. Samuelson, S.T. Rosen, and T.M. Kuzel Phase II trial of all-trans retinoic acid (ATRA) in the treatment of relapsed/refractory mycosis fungoides/Sézary syndrome (MF/SS) Blood 94 1999 97a
90. A.L. Cheng, I.J. Su, C.C. Chen, H.F. Tien, J.D. Lay, and B.R. Chen et al. Use of retinoic acids in the treatment of peripheral T-cell lymphoma: a pilot study J Clin Oncol 12 1994 1185 1192
91. J.M. Chow, A.L. Cheng, I.J. Su, and C.H. Wang 13-cis-retinoic acid induces cellular-differentiation and durable remission in refractory cutaneous Ki-1 lymphoma Cancer 67 1991 2490 2494
92. J.F. Kessler, S.E. Jones, N. Levine, P.J. Lynch, A.R. Booth, and F.L. Meyskens Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides) Arch Dermatol 123 1987 201 204
93. L. Molin, K. Thomsen, G. Volden, A. Aronsson, H. Hammar, and L. Hellbe et al. Oral retinoids in mycosis fungoides and Sézary syndrome: a comparison of isotretinoin and etretinate. A study from the Scandinavian Mycosis Fungoides Group Acta Derm Venereol 67 1987 232 236
94. A.L. Claudy, B. Rouchouse, S. Boucheron, and J.C. Lepetit Treatment of cutaneous lymphoma with etretinate Brit J Dermatol 109 1983 49 56
95. J.F. Kessler, N. Levine, F.L. Meyskens, P.J. Lynch, and S.E. Jones Treatment of cutaneous T-cell lymphoma (mycosis fungoides) with 13-cis-retinoic acid Lancet 1 1983 1345 1347
96. S.K. Richardson, S.B. Newton, T.L. Bach, J.B. Budgin, B.M. Benoit, and J.H. Lin et al. Bexarotene blunts malignant T-cell chemotaxis in Sézary syndrome: reduction of chemokine receptor 4-positive lymphocytes and decreased chemotaxis to thymus and activation-regulated chemokine Am J Hematol 82 2007 792 797
97. M. Duvic, K. Hymes, P. Heald, D. Breneman, A.G. Martin, and P. Myskowski et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results J Clin Oncol 19 2001 2456 2471
98. M. Duvic, A.G. Martin, Y. Kim, E. Olsen, G.S. Wood, and C.A. Crowley et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma Arch Dermatol 137 2001 581 593
99. R.A. Abbott, S.J. Whittaker, S.L. Morris, R. Russell-Jones, T. Hung, and S.J. Bashir et al. Bexarotene therapy for mycosis fungoides and Sézary syndrome Br J Dermatol 160 2009 1299 1307
100. C. Querfeld, S.T. Rosen, J. Guitart, A. Rademaker, B.B. Fung, and W. Posten et al. Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous T-cell lymphoma J Am Acad Dermatol 51 2004 25 32
101. R. Talpur, S. Ward, N. Apisarnthanarax, J. Breuer-Mcham, and M. Duvic Optimizing bexarotene therapy for cutaneous T-cell lymphoma J Am Acad Dermatol 47 2002 672 684
102. F. Singh, and M.G. Lebwohl Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series J Am Acad Dermatol 51 2004 570 573
103. P. Tsirigotis, V. Pappa, S. Papageorgiou, V. Kapsimali, V. Giannopoulou, and I. Kaitsa et al. Extracorporeal photopheresis in combination with bexarotene in the treatment of mycosis fungoides and Sézary syndrome Br J Dermatol 156 2007 1379 1381
104. D.J. Straus, M. Duvic, T. Kuzel, S. Horwitz, M.F. Demierre, and P. Myskowski et al. Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma Cancer 109 2007 1799 1803
105. S. Whittaker, P. Ortiz, R. Dummer, A. Ranki, B. Hasan, and B. Meulemans et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056) Br J Dermatol 167 2012 678 687
106. C. D'Acunto, C. Gurioli, and I. Neri Plaque stage mycosis fungoides treated with bexarotene at low dosage and UVB-NB J Dermatolog Treat 21 2010 45 48
107. E.A. Olsen, and P.A. Bunn Interferon in the treatment of cutaneous T-cell lymphoma Hematol Oncol Clin North Am 9 1995 1089 1107
108. E.A. Olsen Interferon in the treatment of cutaneous T-cell lymphoma Dermatol Ther 16 2003 311 321
109. E.A. Olsen, F.F. Kelly, R.T. Vollmer, D.A. Buddin, and P.K. Weck Comparative study of systemic interferon alfa-nl and isotretinoin in the treatment of resistant condylomata acuminata J Am Acad Dermatol 20 1989 1023 1030
110. E.A. Olsen, S.T. Rosen, R.T. Vollmer, D. Variakojis, H.H. Roenigk Jr., and N. Diab et al. Interferon alfa-2a in the treatment of cutaneous T cell lymphoma J Am Acad Dermatol 20 1989 395 407
111. O. Jumbou, J.M. N'Guyen, M.H. Tessier, B. Legoux, and B. Dreno Long-term follow-up in 51 patients with mycosis fungoides and Sézary syndrome treated by interferon-alfa Br J Dermatol 140 1999 427 431
112. R. Stadler, and H.G. Otte Combination therapy of cutaneous T cell lymphoma with interferon alpha-2a and photochemotherapy Recent Results Cancer Res 139 1995 391 401
113. E. Dippel, H. Schrag, S. Goerdt, and C.E. Orfanos Extracorporeal photopheresis and interferon-alpha in advanced cutaneous T-cell lymphoma Lancet 350 1997 32 33
114. K. Ferenczi, N. Yawalkar, D. Jones, and T.S. Kupper Monitoring the decrease of circulating malignant T cells in cutaneous T-cell lymphoma during photopheresis and interferon therapy Arch Dermatol 139 2003 909 913
115. H.R. Haley, D.A. Davis, and W.M. Sams Durable loss of a malignant T-cell clone in a stage IV cutaneous T-cell lymphoma patient treated with high-dose interferon and photopheresis J Am Acad Dermatol 41 1999 880 883
116. A.H. Rook, M.B. Prystowsky, M. Cassin, M. Boufal, and S.R. Lessin Combined therapy for Sézary syndrome with extracorporeal photochemotherapy and low-dose interferon alfa therapy. Clinical, molecular, and immunologic observations Arch Dermatol 127 1991 1535 1540
117. E.C. Vonderheid, R.D. Bigler, A.S. Greenberg, S.J. Neukum, and B. Micaily Extracorporeal photopheresis and recombinant interferon alfa 2b in Sézary syndrome. Use of dual marker labeling to monitor therapeutic response Am J Clin Oncol 17 1994 255 263
118. E.H. Kaplan, S.T. Rosen, D.B. Norris, H.H. Roenigk Jr., S.R. Saks, and P.A. Bunn Jr. Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma J Natl Cancer Inst 82 1990 208 212
119. S. Arulogun, H.M. Prince, P. Gambell, S. Lade, G. Ryan, and E. Eaton et al. Extracorporeal photopheresis for the treatment of Sézary syndrome using a novel treatment protocol J Am Acad Dermatol 59 2008 589 595
120. C. Berger, K. Hoffmann, J.G. Vasquez, S. Mane, J. Lewis, and R. Filler et al. Rapid generation of maturationally synchronized human dendritic cells: contribution to the clinical efficacy of extracorporeal photochemotherapy Blood 116 2010 4838 4847
121. R. Edelson, C. Berger, F. Gasparro, B. Jegasothy, P. Heald, and B. Wintroub et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results N Engl J Med 316 1987 297 330
122. R. Knobler, M. Duvic, C. Querfeld, D. Straus, S. Horwitz, and J. Zain et al. Long-term follow-up and survival of cutaneous T-cell lymphoma patients treated with extracorporeal photopheresis Photodermatol Photoimmunol Photomed 28 2012 250 257
123. M. Duvic, J.P. Hester, and N.A. Lemak Photopheresis therapy for cutaneous T-cell lymphoma J Am Acad Dermatol 35 1996 573 579
124. T. Dani, and R. Knobler Extracorporeal photoimmunotherapy-photopheresis Front Biosci (Landmark Ed) 14 2009 4769 4777
125. R.L. Edelson Sézary syndrome, cutaneous T-cell lymphoma, and extracorporeal photopheresis Arch Dermatol 135 1999 600 601
126. M. Duvic, N. Chiao, and R. Talpur Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma J Cutan Med Surg 7 2003 3 7
127. L.Y. McGirt, C. Thoburn, A. Hess, and E.C. Vonderheid Predictors of response to extracorporeal photopheresis in advanced mycosis fungoides and Sézary syndrome Photodermatol Photoimmunol Photomed 26 2010 182 191
128. K.R. Suchin, A.J. Cucchiara, S.L. Gottleib, J.T. Wolfe, B.J. DeNardo, and W.H. Macey et al. Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution Arch Dermatol 138 2002 1054 1060
129. U. Wollina, A. Looks, J. Meyer, B. Knopf, H.J. Koch, and K. Liebold et al. Treatment of cutaneous T cell lymphoma stage II with interferon-alpha-2a and extracorporeal photochemotherapy: a prospective controlled trial Ann N Y Acad Sci 941 2001 210 213
130. E. Bisaccia, J. Gonzalez, M. Palangio, J. Schwartz, and A.S. Klainer Extracorporeal photochemotherapy alone or with adjuvant therapy in the treatment of cutaneous T-cell lymphoma: a 9-year retrospective study at a single institution J Am Acad Dermatol 43 2000 263 271
131. S.L. Gottlieb, J.T. Wolfe, F.E. Fox, B.J. DeNardo, W.H. Macey, and P.G. Bromley et al. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution J Am Acad Dermatol 35 1996 946 957
132. R. Talpur, M.F. Demierre, L. Geskin, E. Baron, S. Pugliese, and K. Eubank et al. Multicenter photopheresis intervention trial in early-stage mycosis fungoides Clin Lymphoma Myeloma Leukemia 11 2011 219 227
133. R.A. Clark, R. Watanabe, J.E. Teague, C. Schlapbach, M.C. Tawa, and N. Adams et al. Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients Sci Transl Med 4 2012 117ra7
134. W.M. Siders, J. Shields, C. Garron, Y. Hu, P. Boutin, and S. Shankara et al. Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models Leuk Lymphoma 51 2010 1293 1304
135. Y.P. Hu, M.J. Turner, J. Shields, M.S. Gale, E. Hutto, and B.L. Roberts et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model Immunology 128 2009 260 270
136. H. Lowenstein, A. Shah, A. Chant, and A. Khan Different mechanisms of Campath-1H-mediated depletion for CD4 and CD8 T cells in peripheral blood Transpl Int 19 2006 927 936
137. L. Alinari, L. Geskin, T. Grady, R.A. Baiocchi, M.A. Bechtel, and P. Porcu Subcutaneous alemtuzumab for Sézary syndrome in the very elderly Leuk Res 32 2008 1299 1303
138. - subset in the identification of circulating Sézary cells Br J Dermatol 144 2001 125 135
139. O. Gautschi, N. Blumenthal, M. Streit, M. Solenthaler, T. Hunziker, and R. Zenhausern Successful treatment of chemotherapy-refractory Sézary syndrome with alemtuzumab (Campath-1H) Eur J Haematol 72 2004 61 63
140. G.A. Kennedy, J.F. Seymour, M. Wolf, H. Januszewicz, J. Davison, and C. McCormack et al. Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab Eur J Haematol 71 2003 250 256
141. C. Querfeld, N. Mehta, S.T. Rosen, J. Guitart, A. Rademaker, and P. Gerami et al. Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center Leuk Lymphoma 50 2009 1969 1976
142. P.L. Zinzani, L. Alinari, M. Tani, M. Fina, S. Pileri, and M. Baccarani Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma Haematologica 90 2005 702 703
143. J. Lundin, H. Hagberg, R. Repp, E. Cavallin-Stahl, S. Freden, and G. Juliusson et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sézary syndrome Blood 101 2003 4267 4272
144. M.G. Bernengo, P. Quaglino, A. Comessatti, M. Ortoncelli, M. Novelli, and F. Lisa et al. Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients Haematologica 92 2007 784 794
145. C. Tiffon, J. Adams, L. van der Fits, S. Wen, P. Townsend, and A. Ganesan et al. The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells Br J Pharmacol 162 2011 1590 1602
146. R. Dummer, M. Beyer, K. Hymes, M.T. Epping, R. Bernards, and M. Steinhoff et al. Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition Leuk Lymphoma 53 2012 1501 1508
147. E.A. Olsen, Y.H. Kim, T.M. Kuzel, T.R. Pacheco, F.M. Foss, and S. Parker et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma J Clin Oncol 25 2007 3109 3115
148. M. Duvic, E.A. Olsen, D. Breneman, T.R. Pacheco, S. Parker, and E.C. Vonderheid et al. Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma Clin Lymphoma Myeloma 9 2009 412 416
149. S.J. Whittaker, M.F. Demierre, E.J. Kim, A.H. Rook, A. Lerner, and M. Duvic et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma J Clin Oncol 28 2010 4485 4491
150. R.L. Piekarz, R. Frye, M. Turner, J.J. Wright, S.L. Allen, and M.H. Kirschbaum et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma J Clin Oncol 27 2009 5410 5417
151. Y.H. Kim, M.F. Demierre, E.J. Kim, A. Lerner, A.H. Rook, and M. Duvic et al. Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin Leuk Lymphoma 54 2013 284 289
152. M.J. Kelly-Sell, Y.H. Kim, S. Straus, B. Benoit, C. Harrison, and K.
153. R. Stadler Cutaneous lymphomas: classification and stage-adjusted therapy [in German] Hautarzt 57 2006 744 755
154. R. Talpur, D.M. Jones, A.J. Alencar, N. Apisarnthanarax, K.L. Herne, and Y. Yang et al. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma J Invest Dermatol 126 2006 575 583
155. D.P. Williams, C.E. Snider, T.B. Strom, and J.R. Murphy Structure/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells J Biol Chem 265 1990 11885 11889
156. M.N. Saleh, C.F. LeMaistre, T.M. Kuzel, F. Foss, L.C. Platanias, and G. Schwartz et al. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides J Am Acad Dermatol 39 1998 63 73
157. E. Olsen, M. Duvic, A. Frankel, Y. Kim, A. Martin, and E. Vonderheid et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma J Clin Oncol 19 2001 376 388
158. H.M. Prince, M. Duvic, A. Martin, W. Sterry, C. Assaf, and Y. Sun et al. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma J Clin Oncol 28 2010 1870 1877
159. M. Duvic, L. Geskin, and H.M. Prince Duration of response in cutaneous T-cell lymphoma patients treated with denileukin diftitox: results from 3 phase III studies Clin Lymphoma Myeloma Leuk 13 2013 377 384
160. H.M. Prince, A.G. Martin, E.A. Olsen, D.P. Fivenson, and M. Duvic Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sézary syndrome Leuk Lymphoma 54 2013 69 75
161. E. Izbicka, A. Diaz, R. Streeper, M. Wick, D. Campos, and R. Steffen et al. Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers Cancer Chemother Pharmacol 64 2009 993 999
162. E.S. Wang, O. O'Connor, Y.H. She, A.D. Zelenetz, F.M. Sirotnak, and M.A.S. Moore Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression Leuk Lymphoma 44 2003 1027 1035
163. F.M. Foss Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma Exp Opin Drug Metabol Toxicol 7 2011 1141 1152
164. H.S. Zackheim, M. Kashani-Sabet, and S.T. Hwang Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients J Am Acad Dermatol 34 1996 626 631
165. H.S. Zackheim, M. Kashani-Sabet, and A. McMillan Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients J Am Acad Dermatol 49 2003 873 878
166. C.J. McDonald, and J.R. Bertino Treatment of mycosis fungoides lymphoma: effectiveness of infusions of methotrexate followed by oral citrovorum factor Cancer Treat Rep 62 1978 1009 1014
167. S.M. Horwitz, Y.H. Kim, F. Foss, J.M. Zain, P.L. Myskowski, and M.J. Lechowicz et al. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma Blood 119 2012 4115 4122
168. F. Foss, S.M. Horwitz, B. Coiffier, N. Bartlett, L. Popplewell, and B. Pro et al. Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study Clin Lymphoma Myeloma Leuk 12 2012 238 243
169. M. Duvic, R. Talpur, S. Wen, R. Kurzrock, C.L. David, and N. Apisarnthanarax Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma Clin Lymphoma Myeloma Leuk 7 2006 51 58
170. E. Marchi, L. Alinari, M. Tani, V. Stefoni, N. Pimpinelli, and E. Berti et al. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients Cancer 104 2005 2437 2441
171. R. Dummer, P. Quaglino, J.C. Becker, B. Hasan, M. Karrasch, and S. Whittaker et al. Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012 J Clin Oncol 30 2012 4091 4097
172. U. Wollina, R. Dummer, N.H. Brockmeyer, H. Konrad, J.O. Busch, and M. Kaatz et al. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma Cancer 98 2003 993 1001
173. R.F. Duarte, N. Schmitz, O. Servitje, and A. Sureda Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma Bone Marrow Transplant 41 2008 597 604
174. Y. Oyama, J. Guitart, T.M. Kuzel, R.K. Burt, and S.T. Rosen High-dose therapy and bone marrow transplantation in cutaneous T-cell lymphoma Hematol Oncol Clin North Am 17 2003 1475 1483
175. M. Duvic, M. Donato, B. Dabaja, H. Richmond, L. Singh, and W. Wei et al. Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sézary syndrome J Clin Oncol 28 2010 2365 2372
176. R.D. Bigler, P. Crilley, B. Micaily, L.W. Brady, D. Topolsky, and S. Bulova et al. Autologous bone marrow transplantation for advanced stage mycosis fungoides Bone Marrow Transplant 7 1991 133 137
177. S. Ingen-Housz-Oro, H. Bachelez, O. Verola, C. Lebbe, J.P. Marolleau, and C. Hennequin et al. High-dose therapy and autologous stem cell transplantation in relapsing cutaneous lymphoma Bone Marrow Transplant 33 2004 629 634
178. E. Olavarria, F. Child, A. Woolford, S.J. Whittaker, J.G. Davis, and C. McDonald et al. T-cell depletion and autologous stem cell transplantation in the management of tumour stage mycosis fungoides with peripheral blood involvement Br J Haematol 114 2001 624 631
179. R. Russell-Jones, F. Child, E. Olavarria, S. Whittaker, M. Spittle, and J. Apperley Autologous peripheral blood stem cell transplantation in tumor-stage mycosis fungoides: predictors of disease-free survival Ann N Y Acad Sci 941 2001 147 154
180. J.C. Sterling, R. Marcus, N.P. Burrows, and S.O. Roberts Erythrodermic mycosis fungoides treated with total body irradiation and autologous bone marrow transplantation Clin Exp Dermatol 20 1995 73 75
181. H.J. Kolb, A. Schattenberg, J.M. Goldman, B. Hertenstein, N. Jacobsen, and W. Arcese et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients Blood 86 1995 2041 2050
182. H.J. Kolb, C. Schmid, A.J. Barrett, and D.J. Schendel Graft-versus-leukemia reactions in allogeneic chimeras Blood 103 2004 767 776
183. R.F. Duarte, C. Canals, F. Onida, I.H. Gabriel, R. Arranz, and W. Arcese et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation J Clin Oncol 28 2010 4492 4499
184. P.A. Wu, Y.H. Kim, P.W. Lavori, R.T. Hoppe, and K.E. Stockerl-Goldstein A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sézary syndrome Biol Blood Marrow Transplant 15 2009 982 990
185. F. Baron, and R. Storb Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders Mol Ther 13 2006 26 41
186. K.E. Herbert, A. Spencer, A. Grigg, G. Ryan, C. McCormack, and H.M. Prince Graft-versus-lymphoma effect in refractory cutaneous T-cell lymphoma after reduced-intensity HLA-matched sibling allogeneic stem cell transplantation Bone Marrow Transplant 34 2004 521 525
187. K. Kahata, S. Hashino, M. Takahata, F. Fujisawa, T. Kondo, and S. Kobayashi et al. Durable remission of Sézary syndrome after unrelated bone marrow transplantation by reduced-intensity conditioning Acta Haematol 120 2008 14 18
188. J.B. Bartlett, K. Dredge, and A.G. Dalgleish The evolution of thalidomide and its IMiD derivatives as anticancer agents Nat Rev Cancer 4 2004 314 322
189. Querfeld C, Rosen ST, Guitart J, Duvic M, Kim YH, Dusza SW, Kuzel TM. Phase II multicenter trial of lenalidomide: clinical and immunomodulatory effects in patients with CTCL. 53rd ASH (American Society of Hematology) Annual Meeting and Exposition San Diego, California, December 12, 2011.
190. A.M. Krieg Therapeutic potential of Toll-like receptor 9 activation Nat Rev Drug Discov 5 2006 471 484
191. Y.H. Kim, M. Girardi, M. Duvic, T. Kuzel, B.K. Link, and L. Pinter-Brown et al. Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma J Am Acad Dermatol 63 2010 975 983
192. M. Duvic, M.L. Sherman, G.S. Wood, T.M. Kuzel, E. Olsen, and F. Foss et al. A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides J Am Acad Dermatol 55 2006 807 813
193. C. Querfeld, S.T. Rosen, J. Guitart, A. Rademaker, F. Foss, and R. Gupta et al. Phase II trial of subcutaneous injections of human recombinant interleukin-2 for the treatment of mycosis fungoides and Sézary syndrome J Am Acad Dermatol 56 2007 580 583
194. A.H. Rook, T.M. Kuzel, and E.A. Olsen Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2 Hematol Oncol Clin North Am 17 2003 1435 1448
195. A.H. Rook, M.H. Zaki, M. Wysocka, G.S. Wood, M. Duvic, and L.C. Showe et al. The role for interleukin-12 therapy of cutaneous T cell lymphoma Ann N Y Acad Sci 941 2001 177 184
196. Y.H. Kim, M. Duvic, E. Obitz, R. Gniadecki, L. Iversen, and A. Osterborg et al. Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma Blood 109 2007 4655 4662
197. H. Yano, T. Ishida, A. Inagaki, T. Ishii, J. Ding, and S. Kusumoto et al. Defucosylated anti CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: a novel immunotherapy for aggressive/refractory mycosis fungoides and Sézary syndrome Clin Cancer Res 13 2007 6494 6500
198. T. Han, U.M. Abdel-Motal, D.K. Chang, J. Sui, A. Muvaffak, and J. Campbell et al. Human anti-CCR4 minibody gene transfer for the treatment of cutaneous T-cell lymphoma PloS One 7 2012 e44455
199. P.B. Olkhanud, D. Baatar, M. Bodogai, F. Hakim, R. Gress, and R.L. Anderson et al. Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells Cancer research 69 2009 5996 6004
200. T.J. Curiel, G. Coukos, L. Zou, X. Alvarez, P. Cheng, and P. Mottram et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival Nat Med 10 2004 942 949
201. D.K. Chang, J. Sui, S. Geng, A. Muvaffak, M. Bai, and R.C. Fuhlbrigge et al. Humanization of an anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cells Mol Cancer Ther 11 2012 2451 2461
202. A. Sors, F. Jean-Louis, C. Pellet, L. Laroche, L. Dubertret, and G. Courtois et al. Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis Blood 107 2006 2354 2363
203. P.L. Zinzani, G. Musuraca, M. Tani, V. Stefoni, E. Marchi, and M. Fina et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma J Clin Oncol 25 2007 4293 4297
204. I.M. Ghobrial, P. Moreau, B. Harris, T. Poon, E. Jourdan, and H. Maisonneuve et al. A multicenter phase II study of single-agent enzastaurin in previously treated Waldenstrom macroglobulinemia Clin Cancer Res 18 2012 5043 5050
205. F. Morschhauser, J.F. Seymour, H.C. Kluin-Nelemans, A. Grigg, M. Wolf, and M. Pfreundschuh et al. A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma Ann Oncol 19 2008 247 253
206. M.J. Robertson, B.S. Kahl, J.M. Vose, S. de Vos, M. Laughlin, and P.J. Flynn et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma J Clin Oncol 25 2007 1741 1746
207. C. Querfeld, M.A. Rizvi, T.M. Kuzel, J. Guitart, A. Rademaker, and S.S. Sabharwal et al. The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway J Invest Dermatol 126 2006 1641 1647
208. C. Querfeld, T.M. Kuzel, Y.H. Kim, P. Porcu, M. Duvic, and A. Musiek et al. Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma Leuk Lymphoma 52 2011 1474 1480
209. M.B. Wozniak, R. Villuendas, J.R. Bischoff, C.B. Aparicio, J.F. Martinez Leal, and P. de La Cueva et al. Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma Haematologica 95 2010 613 621
210. A.S. Paller, E.L. Simpson, L.F. Eichenfield, C.N. Ellis, and A.J. Mancini Treatment strategies for atopic dermatitis: optimizing the available therapeutic options Semin Cutan Med Surg 31 3 Suppl 2012 S10 S17
211. S.M. Levenson, and C.C. Lund Thermal burns Dis Mon 9 1957 1 47